Healthcare data analytics company Health Catalyst (NASDAQ: HCAT) will be reporting results this Monday after market hours. Here’s what you need to know.
Health Catalyst beat analysts’ revenue expectations last quarter, reporting revenues of $74.68 million, down 6.2% year on year. It was a slower quarter for the company, with revenue guidance for next quarter missing analysts’ expectations significantly and EBITDA guidance for next quarter missing analysts’ expectations significantly.
Is Health Catalyst a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Health Catalyst’s revenue to decline 12.9% year on year, a reversal from the 6.3% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Health Catalyst rarely misses Wall Street’s revenue estimates.
Looking at Health Catalyst’s peers in the data analytics segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Palantir Technologies delivered year-on-year revenue growth of 84.7%, beating analysts’ expectations by 6.1%, and CLEAR Secure reported revenues up 19.7%, topping estimates by 3.5%. Palantir Technologies traded down 6.9% following the results while CLEAR Secure was also down 1.2%.
Read our full analysis of Palantir Technologies’s results here and CLEAR Secure’s results here.
There has been positive sentiment among investors in the data analytics segment, with share prices up 26.5% on average over the last month. Health Catalyst is up 49.6% during the same time and is heading into earnings with an average analyst price target of $1.79 (compared to the current share price of $1.52).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
